Ownership history in US BANCORP \DE\ Β· 14 quarters on record
This page tracks every 13F SEC filing in which US BANCORP \DE\ reported a position in SONOMA PHARMACEUTICALS INC (SNOA). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π US BANCORP \DE\ outperformed the S&P 500 by +7.5% annually on this SNOA position. Maximum drawdown during holding period: β28.7%.
π₯ Exceptional β beat the S&P 500 by 7.5% per year on this position.
5 quarters analyzed
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
1 add Β· 0 trims. Bought during 0 of 3 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.0% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size